Aclaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025

Published: 2025-05-08 06:50:00 ET ACRS

Published on 05/08/2025 at 06:50, updated on 05/08/2025 at 10:41

Aclaris Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported revenue was USD 1.46 million compared to USD 2.4 million a year ago. Net loss was USD 15.09 million compared to USD 16.94 million a year ago.

Basic loss per share from continuing operations was USD 0.12 compared to USD 0.24 a year ago. Diluted loss per share from continuing operations was USD 0.12 compared to USD 0.24 a year ago.